Health ❯ Healthcare ❯ Pharmacology
Combination Therapy Clinical Trials Targeted Therapies BTK Inhibitors Therapeutics GLP-1 Receptor Agonists Natural Compounds Cancer Therapies Ambroxol Baxdrostat Combination Therapies Aldosterone Synthase Inhibitors Clinical Efficacy Trastuzumab Deruxtecan CAR T Cell Therapy Lithium Compounds Amyloid-targeting Therapies Antibody-Drug Conjugates Cancer Treatment Therapeutic Targets Corticosteroids Brepocitinib Cannabinoid Therapy Levetiracetam Orforglipron Acoramidis Pilocarpine-Diclofenac Eye Drops PARP Inhibitors Anti-Amyloid Drugs Olezarsen Selective Estrogen Receptor Degraders Repurposed Medications Fenfluramine Eye Drops Dapagliflozin HIF-2α Inhibitors IDO1 Inhibitors Small Molecules In Silico Methods Repurposing Existing Medications RNA Markers Quintuple Agonists Targeting Bacterial Resistance Belantamab Mafodotin Pharmacological Chaperones TYK2-JAK1 Inhibitors Repurposed Drugs LCL768 Bezuclastinib Targeted Therapy Cardiac Myosin Inhibitors NRF2 Inhibitors β2 Agonists Bruton Tyrosine Kinase (BTK) Inhibitors Inhaled Heparin Topical Therapies Belzutifan Bruton’s Tyrosine Kinase Inhibitors Finerenone Oral Therapies Inhaled Therapies Cancer Therapy Ianalumab CETP Inhibitors TYK2 Inhibitors Malaria Treatments Denosumab Galectin-1 Inhibitors Anticancer Drugs Plant-based Therapies Pirtobrutinib Aldosterone Blockers Elinzanetant JAK Inhibitors Eli Lilly Anesthetic Agents Oral Medications Clinical Efficacy of Myosin Inhibitors Antithrombotic Agents Motion Sickness Next-Generation Therapies Alpelisib
Want to see what podcasts are saying about this topic? Search across 130K+ podcasts. Explore Radar
Additional analyses followed by regulatory review will determine whether the amylin-plus-GLP-1 approach becomes a new treatment option for people with type 2 diabetes.
